Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021:175:413-434.
doi: 10.1007/10_2020_144.

Glycoproteomics Technologies in Glycobiotechnology

Kathirvel Alagesan  1   2 , Marcus Hoffmann  3 , Erdmann Rapp  3   4 , Daniel Kolarich  5   6
Affiliations

Glycoproteomics Technologies in Glycobiotechnology

Kathirvel Alagesan et al. Adv Biochem Eng Biotechnol. 2021.

Abstract

Glycosylation is a key factor determining the pharmacological properties of biotherapeutics, including their stability, solubility, bioavailability, pharmacokinetics, and immunogenicity. As such, comprehensive information about glycosylation of biotherapeutics is critical to demonstrate similarity. Regulatory agencies also require extensive documentation of the comprehensive analyses of glycosylation-related critical quality attributes (CQAs) during the development, manufacturing, and release of biosimilars. Mass spectrometry has catalysed tremendous advancements in the characterisation of glycosylation CQAs of biotherapeutics. Here we provide a perspective overview on the MS-based technologies relevant for biotherapeutic product characterisation with an emphasis on the recent developments that allow determination of glycosylation features such as site of glycosylation, sialic acid linkage, glycan structure, and content.

Keywords: Analytics; Biopharmaceuticals; Glycoproteomics; Mass spectrometry.

PubMed Disclaimer

References

    1. Grassi L, Cabrele C (2019) Susceptibility of protein therapeutics to spontaneous chemical modifications by oxidation, cyclization, and elimination reactions. Amino Acids 51:1409–1431. https://doi.org/10.1007/s00726-019-02787-2 - DOI - PubMed
    1. Zhong X, Wright JF (2013) Biological insights into therapeutic protein modifications throughout trafficking and their biopharmaceutical applications. Int J Cell Biol 2013:273086. https://doi.org/10.1155/2013/273086 - DOI - PubMed - PMC
    1. Srebalus Barnes CA, Lim A (2007) Applications of mass spectrometry for the structural characterization of recombinant protein pharmaceuticals. Mass Spectrom Rev 26:370–388. https://doi.org/10.1002/mas.20129 - DOI - PubMed
    1. Rogers RS et al (2017) A view on the importance of “multi-attribute method” for measuring purity of biopharmaceuticals and improving overall control strategy. AAPS J 20:7. https://doi.org/10.1208/s12248-017-0168-3 - DOI - PubMed
    1. Bui LA et al (2015) Key considerations in the preclinical development of biosimilars. Drug Discov Today 20(Suppl 1):3–15. https://doi.org/10.1016/j.drudis.2015.03.011 - DOI - PubMed

LinkOut - more resources